Fox Chase Cancer Center

 

Fox Chase Cancer Center
E

2020 ASCO Update on Advanced RCC: Pembrolizumab + Axitinib vs. Sunitinib - Which Drug Showed Greater Response in the 1st Line Advanced Disease? Did MK-6482 Show Clinical Activity in Clear Cell Disease?

By Fox Chase Cancer Center FEATURING Elizabeth R. Plimack
By Fox Chase Cancer Center FEATURING Elizabeth R. Plimack
0 views
June 26, 2020
Comments 0
Login to view comments. Click here to Login
Videos
12:50
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "The GIANT Trial (EA2186) - Gem & nab-…

Feat. E. Dotan
04:25
Total Health

LS-SCLC Updates - 2023 ASCO® Direct Philadelphia

Feat. J. Bauman
04:35
Total Health

Chemo vs. Chemo + Pembro in 1L Pleural Mesothelioma - 2023 ASCO® Dir…

Feat. J. Bauman
26:42
Total Health

ADAURA & KEYNOTE-671 Trials: Early Stage NSCLC Updates - 2023 AS…

Feat. J. Bauman
06:11
Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "An Outpatient Model for Teclistamab Step-U…

Feat. A. Varshavsky-Yanovsky
21:34
2023 Texas Lung Cancer Conference Coverage

The Evolving Role of Dual Checkpoint Inhibition in Advanced NSCLC

Feat. H. Borghaei
03:05
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Adjuvant Therapies in Renal Cell Carcinoma: Are New Dat…

Feat. M. Zibelman
13:51
Fox Chase Cancer Center

Adjuvant Treatment of NSCLC: ADAURA in Context

Feat. M. Edelman
09:51
Fox Chase Cancer Center

Influence of 1L Chemo on Survival Outcomes of Patients with Advanced…

Feat. B. Miron
08:35
Fox Chase Cancer Center

2L Treatment of Advanced Gastric Cancer: Moving Towards an Opportuni…

Feat. N. Vijayvergia
19:53
Bladder Cancer Symposium: Update on Medical and Surgical Management for the Urologist

2021 Update on Advanced Urothelial Cancer: Navigating 1L and Beyond …

Feat. E. Plimack
12:36
3rd Annual Atlanta Precision Oncology Symposium

Genotype-Directed Therapy for Advanced NSCLC: Overview of Targeted T…

Feat. H. Borghaei
13:52
3rd Annual Atlanta Precision Oncology Symposium

Targeted Therapy for Advanced NSCLC: Efficacy Analysis of RET, KRAS,…

Feat. H. Borghaei
34:34
UChicago Genetics in Clinical Cancer Care: From Family Reunions to the Frontline of Developmental Therapeutics

Immunology & IO in Lynch Syndrome: Immune System, MSI & Here…

Feat. M. J. Hall
16:08
Fox Chase Cancer Center

Genomic Differentiation of Early-Onset CRC: When Should the Screenin…

Feat. J. Meyer
08:15
2020 ASCO Virtual Direct™ Highlights

2020 Update on Radiation Therapy in Lung Cancer: Is High-Dose Twice-…

Feat. H. Borghaei
10:59
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Targeted Therapy in NSCLC: Is Adjuvant Osimertin…

Feat. H. Borghaei
03:24
Fox Chase Cancer Center

2020 ASCO Update on Advanced RCC: Pembrolizumab + Axitinib vs. Sunit…

Feat. E. Plimack
14:38
CancerGRACE

The Role of IO in Bladder Cancer: Potential Benefits in Neoadjuvant …

Feat. E. Plimack, R. Sedhom
10:57
23rd Collaborative Group of the Americas on Inherited Colorectal Cancer Annual Meeting

GI Cancer Risks Associated with Pathogenic Variants (PV) in the Atax…

Feat. M. Hall
19:10
Fox Chase Updates in Bladder and Kidney Cancer 2019

2019 1st Line Systemic Therapy for Metastatic Urothelial Carcinoma: …

Feat. E. Plimack
14:23
Fox Chase Cancer Center

Front Line Therapy in NSCLC: Immunotherapy vs Immunotherapy + Chemo?

Feat. H. Borghaei
20:36
Fox Chase Cancer Center

I-O/Chemo Combination Therapies in NSCLC

Feat. H. Borghaei
09:14
Fox Chase Cancer Center

Second Line Treatment Options in NSCLC

Feat. H. Borghaei